TL;DR: GHRP-2 and GHRP-6 are both growth-hormone-releasing peptides that act on the ghrelin receptor. The practical split: GHRP-6 causes strong, ghrelin-like hunger; GHRP-2 releases modestly more GH with far less appetite. Both can nudge cortisol and prolactin more than the cleaner ipamorelin.
The Core Difference: Same Receptor, Different Side-Effect Profiles
GHRP-2 and GHRP-6 belong to the same family of synthetic peptides known as growth-hormone-releasing peptides (GHRPs). Both are agonists at the growth hormone secretagogue receptor 1a (GHS-R1a) — the same receptor later found to be the natural target of ghrelin, the stomach-derived “hunger hormone.” By activating GHS-R1a on the pituitary and hypothalamus, both peptides trigger a pulse of growth hormone (GH) release and suppress somatostatin, the brake on GH secretion.
GHRP-6 is the elder of the two. Characterised in 1984 by Cyril Bowers and Frank Momany, it was the first synthetic peptide built specifically to release GH through a mechanism entirely separate from growth-hormone-releasing hormone (GHRH). GHRP-2 came later as a more refined analog, engineered to keep the GH-releasing punch while trimming some of the off-target ghrelin-like activity.
That engineering is the whole story. Because GHRP-6 hews closely to ghrelin’s binding behaviour, it is a powerful orexigenic (appetite-stimulating) compound — hunger typically hits within 15–30 minutes of administration in research models. GHRP-2 retains, and slightly exceeds, GHRP-6’s GH-releasing potency but produces noticeably less of that hunger signal. Neither, however, is as receptor-selective as ipamorelin, the later-generation secretagogue designed to release GH with minimal cortisol, prolactin, or appetite effects. You can compare the individual research profiles for GHRP-2 and GHRP-6 to see how each is catalogued.
Side-by-Side Comparison
| Attribute | GHRP-2 | GHRP-6 |
|---|---|---|
| Peptide class | Ghrelin-receptor (GHS-R1a) agonist | Ghrelin-receptor (GHS-R1a) agonist |
| Relative GH potency | Slightly higher peak GH output | Strong, marginally lower than GHRP-2 |
| Appetite stimulation | Mild to moderate | Strong — closest to natural ghrelin |
| Cortisol / ACTH effect | Present, dose-dependent | Present, dose-dependent |
| Prolactin effect | Mild elevation at higher doses | Mild to moderate at higher doses |
| Receptor selectivity | Moderate | Lower (more ghrelin-like) |
| Year characterised | Later analog | 1984 (first-in-class GHRP) |
| Common research pairing | GHRH analog (e.g. CJC-1295 / Mod GRF) | GHRH analog (e.g. CJC-1295 / Mod GRF) |
The differences in potency between the two are modest and dose-dependent; the appetite gap is the more reliable, reproducible distinction in the literature. Both sit alongside a GHRH analog in most study designs because a GHRP plus a GHRH analog release far more GH together than either alone.
What the Research Shows
The honest starting point: most of what is documented for these peptides comes from small early-phase human studies, animal work, and mechanistic research from the 1980s to 2000s. Neither GHRP-2 nor GHRP-6 is an approved medicine in the EU or elsewhere, and neither has been through the large, long-term human trials that anchor accepted therapeutics.
On GH release, GHRP-6’s foundational characterisation (Bowers, Momany, Reynolds & Hong, 1984) established that a small hexapeptide could specifically and dose-dependently release GH both in vitro and in vivo. Later human physiology work (Pandya et al., 1998) showed GHRP-6 requires endogenous hypothalamic GHRH for a maximal GH response — evidence that GHRPs and GHRH act through complementary, synergistic pathways rather than the same one. This is the mechanistic basis for pairing a GHRP with a GHRH analog such as CJC-1295 / Mod GRF 1-29 in research protocols.
On appetite, the standout human data concern GHRP-2. Laferrère and colleagues (2005), publishing in The Journal of Clinical Endocrinology & Metabolism, infused GHRP-2 into healthy lean men and found they ate roughly 36% more than under saline — direct confirmation that GHRP-2 acts like ghrelin to stimulate food intake in humans, not just animals. GHRP-6’s appetite effect is generally described as even stronger, but much of that comparative ranking rests on animal food-intake models and mechanistic reasoning rather than head-to-head human trials.
Qualitative ranking from the literature; ipamorelin shown as the low-appetite reference.
On the broader ghrelin story, the 1999 discovery of ghrelin as the endogenous ligand for GHS-R1a (Kojima et al., Nature) retrospectively explained why both peptides drive hunger: they are, functionally, ghrelin mimetics. This is also why the “cleaner” secretagogue ipamorelin was later developed (Raun et al., 1998) — to decouple GH release from the ghrelin-linked appetite, cortisol, and prolactin effects that GHRP-6 and, to a lesser degree, GHRP-2 carry.
Be clear about the evidence gap: peak-GH potency rankings, cortisol/prolactin comparisons, and “which is better” claims are largely extrapolated from mixed sources of varying quality. Treat confident numeric comparisons with caution.
Cortisol, Prolactin, and Why Selectivity Matters
The reason researchers distinguish these peptides from ipamorelin comes down to receptor selectivity. Because GHRP-2 and GHRP-6 bind GHS-R1a in a way that echoes ghrelin, they can also nudge the hypothalamic-pituitary-adrenal axis, producing dose-dependent rises in cortisol and ACTH, plus mild prolactin elevation — most noticeable at higher doses or above the receptor-saturating threshold. These effects are generally described as modest, but they are the trade-off for the older GHRPs’ strong GH output.
Ipamorelin, by contrast, was specifically engineered to release GH without meaningfully touching cortisol or prolactin, which is why it is often the reference point for “clean” GH secretagogue research. That does not make GHRP-2 or GHRP-6 obsolete in a research context — GHRP-6’s potent appetite effect makes it a useful tool for studying orexigenic pathways and cachexia models precisely because it mimics ghrelin so faithfully.
How the Two Are Paired in Research Protocols
A GHRP is rarely studied alone. The signature GH response comes from combining a GHRP with a GHRH analog: the GHRP suppresses somatostatin and directly triggers release while the GHRH analog amplifies the pulse, so the two together release substantially more GH than either in isolation (Pandya et al., 1998). This is the same synergy documented across the GHRH-plus-GHRP literature.
In practice, that means both GHRP-2 and GHRP-6 appear in study designs alongside a short-acting GHRH analog such as Mod GRF 1-29, timed so both compounds’ brief windows overlap into a single coordinated pulse. The choice between GHRP-2 and GHRP-6 within such a design usually turns on whether the appetite effect is wanted (GHRP-6 for orexigenic models) or unwanted (GHRP-2, or ipamorelin, when appetite is a confounder). Researchers modelling these combinations often work through reconstitution and unit conversions with a peptide dosing calculator to keep comparisons consistent across compounds.
Frequently Asked Questions
What is the main difference between GHRP-2 and GHRP-6?
Both activate the ghrelin receptor (GHS-R1a) to release growth hormone. The key practical difference is appetite: GHRP-6 strongly stimulates hunger, closely mimicking ghrelin, while GHRP-2 releases slightly more GH with much less appetite stimulation. GHRP-6 is the older, first-in-class peptide; GHRP-2 is a refined analog.
Which is more potent for growth hormone release?
GHRP-2 is generally reported to produce marginally higher peak GH output than GHRP-6, though the difference is modest and dose-dependent. Both are strong GH secretagogues. Comparative potency figures come from mixed research sources rather than large head-to-head human trials, so treat precise rankings with appropriate caution.
Why does GHRP-6 cause so much hunger?
GHRP-6 binds the ghrelin receptor in a way that closely mirrors natural ghrelin, the body’s primary hunger hormone. This makes it a functional ghrelin mimetic with potent orexigenic effects, typically appearing within 15–30 minutes in research models. GHRP-2 also increases appetite but was engineered to reduce this ghrelin-like effect.
Do GHRP-2 and GHRP-6 raise cortisol and prolactin?
Both can produce dose-dependent increases in cortisol, ACTH, and prolactin, most noticeable at higher doses. These effects stem from their lower receptor selectivity compared with ipamorelin, which was specifically designed to release GH without meaningfully affecting cortisol or prolactin. The elevations with GHRP-2 and GHRP-6 are generally described as modest.
Why are these peptides paired with a GHRH analog?
A GHRP alone raises GH modestly. Pairing it with a GHRH analog such as CJC-1295 or Mod GRF 1-29 exploits a documented synergy: the GHRP suppresses somatostatin and triggers release while the GHRH analog amplifies the pulse, so together they release far more GH than either alone. Their short windows are timed to overlap.
Are GHRP-2 or GHRP-6 approved for human use?
No. Neither GHRP-2 nor GHRP-6 is an approved medicine in the EU or elsewhere. The available human data come from small, early-phase research studies, with much detail extrapolated from animal and mechanistic work. Both are handled strictly as research chemicals for laboratory and educational reference, not for human administration.
References
-
Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology, 1984;114(5):1537–1545.
-
Laferrère B, Abraham C, Russell CD, Bowers CY. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. The Journal of Clinical Endocrinology & Metabolism, 2005;90(2):611–614.
-
Pandya N, DeMott-Friberg R, Bowers CY, Barkan AL, Jaffe CA. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. The Journal of Clinical Endocrinology & Metabolism, 1998;83(4):1186–1189.
-
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 1999;402(6762):656–660.
-
Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998;139(5):552–561.
-
Bowers CY. Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences, 1998;54(12):1316–1329.
This article is provided for scientific and educational reference only. All compounds discussed are intended strictly for in-vitro laboratory research use. Nothing here is medical advice, and no statement should be read as a therapeutic claim, an endorsement, or a human dosing recommendation. GHRP-2 and GHRP-6 are not approved for human consumption.